Analyses of TGF-β EV levels in advanced NSCLC patients before and during immunotherapy (n = 33) revealed that high baseline TGF-β levels were associated with a lack of response to checkpoint inhibitors, shorter PFS and OS [81]. Here, TGFB1 is linked to non-small cell lung carcinoma.